- Home
- HRTX vs KROS Comparison
HRTX vs KROS Comparison
Compare HRTX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRTX | KROS |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.3M | 206.0M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HRTX | KROS |
|---|---|---|
| Price | $0.43 | $11.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.50 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 3.4M | 313.0K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | $154,904,000.00 | ★ $243,864,000.00 |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | $2,751.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.38 | $9.69 |
| 52 Week High | $2.04 | $22.55 |
Technical Indicators
Market Signals| Indicator | HRTX | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 49.32 |
| Support Level | $0.38 | $10.83 |
| Resistance Level | $0.46 | $11.55 |
| Average True Range (ATR) | 0.03 | 0.56 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 59.40 | 35.28 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.